Recent Updates
Recently added Catalysts
SPRB Positive Sentiment

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Monday, August 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spruce Biosciences has appointed Dr. Jessica Cohen Pfeffer as Vice President of Clinical Development. With over ten years of experience in the biopharmaceutical industry, she is expected to strengthen the company's leadership. Spruce focuses on developing therapies for neurological disorders, addressing significant unmet medical needs.
Price reaction · baseline $42.83 (2026-07-31 close) · hit pre-market · clean, no other SPRB news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a seasoned professional to enhance leadership.
  • Dr. Cohen Pfeffer has over a decade of relevant experience.
  • Focus on developing therapies for neurological disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
11.9%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
SPR001
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective today. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning c

Frequently Asked Questions

Who is the new Vice President of Clinical Development at Spruce?

Dr. Jessica Cohen Pfeffer has been appointed as Vice President of Clinical Development.

What experience does Dr. Cohen Pfeffer bring?

She brings over a decade of experience in the biopharmaceutical industry.

What is Spruce Biosciences focused on?

Spruce is focused on developing therapies for neurological disorders.

When did Dr. Cohen Pfeffer's appointment take effect?

Her appointment took effect immediately.

ShareAdd on Google
Tags: SPRB Viatris Investor Conferences Healthcare Spruce Biosciences Jessica Cohen Pfeffer clinical development neurological disorders biopharmaceutical
Last updated: Aug 3, 2026

Biotech snapshot

Cash runway
$54M liquidity · $3M/mo burn
~16 mo
Low dilution risk
Lead asset
SPR001Phase 2
Congenital Adrenal Hyperplasia →

Catalyst track record

+42%
best trade around SPRB's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SPRB.

See every catalyst's timing & PoA →